Agios Q2 2022: PYRUKYND revenue $3.1M; net loss $91.8M; CEO transition to Brian Goff

AGIOS PHARMACEUTICALS, INC.

2022-Q2 EPS reported -$3.41 revenue$6,414,000

Q2 2022 net loss from continuing ops $91.8M vs $82.8M Q2 2021; R&D expenses rose to $74.5M.
PYRUKYND generated $3.1M net U.S. revenue in first full quarter after Feb 2022 FDA approval.
Cash, equivalents, marketable securities $1.1B, down from $1.7B; expects to fund to cash-flow positivity.
Brian Goff becomes CEO Aug 8; current CEO Jackie Fouse transitions to Chair of Board.
Five pivotal PYRUKYND studies enrolling across thalassemia, sickle cell, pediatric PK deficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.